Cancer center tests new drug duo for Tough-to-Treat uterine cancer
NCT ID NCT05036681
Summary
This study tested a combination of two drugs, futibatinib and pembrolizumab, for people with a specific type of advanced endometrial (uterine) cancer that had spread and was not responding well to standard chemotherapy. The goal was to see if this new combination could shrink tumors and be tolerated by patients. The trial was small and has been stopped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.